Regorafenib based drugs: price, availability and description

Regorafenib is an oral multi-kinase inhibitor that targets angiogenic, stromal, and oncogenic receptor tyrosine kinases to block tumor growth and new blood vessel formation. It is indicated for the treatment of metastatic colorectal cancer (CRC), gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC) in patients who have been previously treated with other standard therapies.